CNS transporters and drug delivery in epilepsy

Current Pharmaceutical Design

Volumn 20, Issue 10, 2014, Pages 1534-1542

  Potschka, Heidrun ^a   Luna Munguia, Hiram ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Blood brain barrier; Drug resistance; p glycoprotein; Seizure; Transporter

Indexed keywords

BIOLOGICAL MARKER; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CELECOXIB; CYCLOOXYGENASE 2; ESLICARBAZEPINE ACETATE; ETHOSUXIMIDE; ETIRACETAM; LAMOTRIGINE; LICARBAZEPINE; MONOCARBOXYLATE TRANSPORTER 1; MULTIDRUG RESISTANCE PROTEIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TARIQUIDAR; TOPIRAMATE; VALPROIC ACID; VERAPAMIL;

ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DELIVERY SYSTEM; DRUG RESPONSE; EPILEPSY; EPILEPTIC STATE; GENETIC ANALYSIS; HUMAN; INTRACTABLE EPILEPSY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPORAL LOBE EPILEPSY; UPREGULATION;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; EPILEPSY; HUMANS; MEMBRANE TRANSPORT PROTEINS; RATS;

EID: 84897385708     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990461     Document Type: Article

References (103)

1. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011; 365: 919-26.
2. Loscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011; 52: 657-78.
3. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009.
4. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62: 382-9.
5. Picot MC, Baldy-Moulinier M, Daures JP, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 2008; 49: 1230-8.
6. Loscher W, Sills GJ. Drug resistance in epilepsy: why is a simple explanation not enough? Epilepsia 2007; 48: 2370-2.
7. Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 2008; 8: 127-30.
8. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602.
9. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86-98.
10. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25: 423-9.
11. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005; 76: 22-76.
12. Chishty M, Reichel A, Siva J, Abbott NJ, Begley DJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target 2001; 9: 223-8.
13. Loscher W, Luna-Tortos C, Romermann K, Fedrowitz M. Do ATPbinding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des 2011; 17: 2808-28.
14. Lauritzen F, Perez EL, Melillo ER, et al. Altered expression of brain monocarboxylate transporter 1 in models of temporal lobe epilepsy. Neurobiol Dis 2012; 45: 165-76.
15. Lauritzen F, de Lanerolle NC, Lee TS, et al. Monocarboxylate transporter 1 is deficient on microvessels in the human epileptogenic hippocampus. Neurobiol Dis 2011; 41: 577-84.
16. Peura L, Malmioja K, Laine K, et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Mol Pharm 2011; 8: 1857-66.
17. Dickens D, Owen A, Alfirevic A, et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol 2012; 83: 805-14.
18. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-8.
19. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999; 36: 179-194.
20. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995; 36: 1-6.
21. Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001; 42: 1501-6.
22. Sisodiya SM, Heffernan J, Squier MV. Over-expression of Pglycoprotein in malformations of cortical development. Neuroreport 1999; 10: 3437-41.
23. Marroni M, Marchi N, Cucullo L, Abbott NJ, Signorelli K, Janigro D. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy. Curr Drug Targets 2003; 4: 297-304.
24. Aronica E, Gorter JA, Ramkema M, et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004; 45: 441-51.
25. Lazarowski A, Lubieniecki F, Camarero S, et al. Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. Pediatr Neurol 2004; 30: 102-6.
26. Marchi N, Hallene KL, Kight KM, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2004; 2: 37.
27. Kubota H, Ishihara H, Langmann T, et al. Distribution and functional activity of P-glycoprotein and multidrug resistanceassociated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 2006; 68: 213-28.
28. Ak H, Ay B, Tanriverdi T, et al. Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. Seizure 2007; 16: 493-503.
29. Lazarowski A, Ramos AJ, Garcia-Rivello H, Brusco A, Girardi E. Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model. Cell Mol Neurobiol 2004; 24: 77-85.
30. Lazarowski A, Massaro M, Schteinschnaider A, Intruvini S, Sevlever G, Rabinowicz A. Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy. Ther Drug Monit 2004; 26: 44-6.
31. Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999; 21: 731-4.
32. Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003; 118: 417-29.
33. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125: 22-31.
34. Sisodiya SM, Thom M. Widespread upregulation of drugresistance proteins in fatal human status epilepticus. Epilepsia 2003; 44: 261-4.
35. Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res 1999; 126: 509-16.
36. Seegers U, Potschka H, Loscher W. Transient increase of Pglycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res 2002; 51: 257-68.
37. Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce Pglycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002; 22: 5833-9.
38. Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Löscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004; 123: 751-9.
39. Bankstahl JP, Löscher W. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res 2008.
40. van Vliet E, Aronica E, Redeker S, et al. Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats. Epilepsy Res 2004; 60: 203-13.
41. Seegers U, Potschka H, Loscher W. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia 2002; 43: 675-84.
42. Volk HA, Potschka H, Löscher W. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 2004; 58: 67-79.
43. Potschka H, Volk HA, Loscher W. Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. Neuroreport 2004; 15: 1657-61.
44. Volk HA, Loscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of Pglycoprotein compared with rats with drug-responsive seizures. Brain 2005; 128: 1358-68.
45. Volk H, Potschka H, Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 2005; 53: 517-31.
46. Hoffmann K, Gastens AM, Volk HA, Loscher W. Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. Epilepsy Res 2006; 69: 1-14.
47. Kuteykin-Teplyakov K, Brandt C, Hoffmann K, Loscher W. Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. Epilepsia 2009; 50: 887-97.
48. van Vliet EA, Redeker S, Aronica E, Edelbroek PM, Gorter JA. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 2005; 46: 1569-80.
49. Aronica E, Gorter JA, Redeker S, et al. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 2005; 46: 849-57.
50. Sills GJ, Kwan P, Butler E, et al. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002; 3: 427-432.
51. Potschka H, Loscher W. In vivo evidence for P-glycoproteinmediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001; 42: 1231-40.
52. Potschka H, Fedrowitz M, Loscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the bloodbrain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002; 327: 173-6.
53. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003; 306: 124-31.
54. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001; 12: 3557-60.
55. Polli JW, Wring SA, Humphreys JE, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299: 620-8.
56. Reichel A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chem Biodivers 2009; 6: 2030-49.
57. Lentz KA, Hayashi J, Lucisano LJ, Polli JE. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. Int J Pharm 2000; 200: 41-51.
58. Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 2011.
59. Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008; 55: 1364-75.
60. Pachot JI, Botham RP, Haegele KD, Hwang K. Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J Pharm Pharm Sci 2003; 6: 1-12.
61. Luna-Tortos C, Rambeck B, Jurgens UH, Loscher W. The Antiepileptic Drug Topiramate is a Substrate for Human Pglycoprotein but Not Multidrug Resistance Proteins. Pharm Res 2009.
62. Zhang C, Kwan P, Zuo Z, Baum L. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. Life Sci 2010; 86: 899-905.
63. Zhang C, Zuo Z, Kwan P, Baum L. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 2011; 52: 1894-904.
64. Luna-Tortos C, Fedrowitz M, Loscher W. Evaluation of transport of common antiepileptic drugs by human multidrug resistanceassociated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 2010; 58: 1019-32.
65. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-65.
66. Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 2011; 12: 621-30.
67. Kuhnle M, Egger M, Muller C, et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the pglycoprotein (ABCB1) modulator tariquidar. J Med Chem 2009; 52: 1190-7.
68. Pick A, Muller H, Wiese M. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 2008; 16: 8224-36.
69. van Vliet EA, van Schaik R, Edelbroek PM, et al. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 2007; 322: 141-7.
70. van Vliet EA, van Schaik R, Edelbroek PM, et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006; 47: 672-80.
71. Brandt C, Bethmann K, Gastens AM, Loscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-ofprinciple in a rat model of temporal lobe epilepsy. Neurobiol Dis 2006; 24: 202-11.
72. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther 2005; 314: 725-31.
73. Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004; 38: 1631-4.
74. Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res 2009; 85: 89-95.
75. Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005; 46: 967-9.
76. Schmitt FC, Dehnicke C, Merschhemke M, Meencke HJ. Verapamil attenuates the malignant treatment course in recurrent status epilepticus. Epilepsy Behav 2010; 17: 565-8.
77. Pirker S, Baumgartner C. Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil. Eur J Neurol 2011; 18: e151.
78. Macphee GJ, McInnes GT, Thompson GG, Brodie MJ. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1986; 1: 700-3.
79. Jambroszyk M, Tipold A, Potschka H. Add-on treatment with verapamil in pharmacoresistant canine epilepsy. Epilepsia 2011; 52: 284-91.
80. Potschka H. Targeting the brain--surmounting or bypassing the blood-brain barrier. Handb Exp Pharmacol 2010: 411-31.
81. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol Ther 2010; 125: 118-27.
82. Zhu HJ, Liu GQ. Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptormediated mechanism. Life Sci 2004; 75: 1313-22.
83. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008; 73: 1444-53.
84. Yu N, Di Q, Liu H, et al. Nuclear factor-kappa B activity regulates brain expression of P-glycoprotein in the kainic acid-induced seizure rats. Mediators Inflamm 2011; 2011: 670613.
85. Zibell G, Unkruer B, Pekcec A, et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009; 56: 849-55.
86. van Vliet EA, Zibell G, Pekcec A, et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010; 58: 404-12.
87. Schlichtiger J, Pekcec A, Bartmann H, et al. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br J Pharmacol 2010; 160: 1062-71.
88. Manabe Y, Anrather J, Kawano T, et al. Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol 2004; 55: 668-75.
89. Abe T, Kunz A, Shimamura M, Zhou P, Anrather J, Iadecola C. The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab 2009; 29: 66-72.
90. Pekcec A, Unkruer B, Schlichtiger J, et al. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein upregulation. J Pharmacol Exp Ther 2009; 330: 939-47.
91. Bankstahl JP, Hoffmann K, Bethmann K, Loscher W. Glutamate is critically involved in seizure-induced overexpression of Pglycoprotein in the brain. Neuropharmacology 2008; 54: 1006-16.
92. Loscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol 1998; 54: 721-41.
93. Sveinbjornsdottir S, Sander JW, Upton D, et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 1993; 16: 165-74.
94. Nurmohamed L, Garcia-Bournissen F, Buono RJ, Shannon MW, Finkelstein Y. Predisposition to epilepsy-Does the ABCB1 gene play a role? Epilepsia 2010.
95. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drugtransporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 2009; 50: 898-903.
96. Haerian BS, Roslan H, Raymond AA, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis. Seizure 2010.
97. Potschka H. Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics 2010; 11: 1427-38.
98. Mairinger S, Erker T, Muller M, Langer O. PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab 2011; 12: 774-92.
99. Langer O, Bauer M, Hammers A, et al. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 2007; 48: 1774-84.
100. Loscher W, Langer O. Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy. Curr Top Med Chem 2010; 10: 1785-91.
101. la Fougere C, Boning G, Bartmann H, et al. Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage 2010; 49: 1406-15.
102. Bartmann H, Fuest C, la Fougere C, et al. Imaging of Pglycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia 2010; 51: 1780-90.
103. Bankstahl JP, Bankstahl M, Kuntner C, et al. A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci 2011; 31: 8803-11.